.png)
Specialist MedTech VC
Catalysing Breakthroughs in Medical Technology
We Are the “D” in R&D
Research creates possibility. Development turns that possibility into impact.
At Bioshore Ventures, we bring together investment capital, MedTech domain expertise and global networks to help medical technology innovations move from research and development into the clinic and, ultimately, into markets around the world.
Our focus is simple: help great medical technologies reach the patients who need them.
Why Bioshore Ventures?
MedTech Domain Expertise
Commercialising medical technology is highly complex. Bringing a new technology to market requires a deep understanding of clinical practice, regulation, reimbursement, healthcare systems, commercial strategy and corporate finance.
Our team understands these challenges firsthand.
The Bioshore Network
Our investor base consists of leading clinicians, surgeons and KOLs across a range of specialties, complemented by senior MedTech industry executives and entrepreneurs who fundamentally understand not only the path to market but how to achieve success in these markets.
This network is our key differentiator.
Founder Partnership
We are more than just a source of investment. Leveraging our domain expertise and vast clinician networks we partner with founders and portfolio company management teams to help bring their technologies to market.
The goal: to materially improve patient outcomes and lower the cost of care.
Focus = Returns
We fundamentally understand the commercialisation journey for medical devices and the premia the majors will pay for clinician endorsed novel technologies.
We believe that sector specialisation and our approach to portfolio construction will deliver superior risk-adjusted returns to our investors.
Core thesis: ASCs
Ambulatory surgery centres (ASCs) will increasingly deliver procedures with lower cost, greater convenience and efficient clinical throughput compared with hospital inpatient care.
We back devices that fit the ASC model unlocking a compelling adoption driver in a high growth delivery channel.
Track Record
Our team has founded, scaled, advised, acquired and funded medical technology businesses across ANZ and internationally for decades.
We understand what it takes to achieve not only commercial success but importantly to engineer a successful exit.
Our Mission
Helping Medical Innovation Make a Real-World Impact
Bioshore Ventures partners with founders and innovators developing breakthrough medical technologies.
We provide more than capital. We bring the experience, knowledge and networks required to help founders make better decisions, overcome commercialisation challenges and maximise the potential of their technology.
From early-stage investment through to clinical and commercial development, we work alongside visionary teams to give their innovations the best possible chance of positively impacting patients around the world.
Capital is only part of the equation. Our network and domain expertise makes the difference.
It’s both what you know AND who you know
" Well connected venture firms gain access to better opportunities which lead to outsized returns…and often these investors are concentrated in established ecosystems."
Pitchbook, Quantitative Perspectives Report, 2025
Bioshore Ventures invests solely in MedTech, leveraging our global networks built up over decades of industry experience streamlining due diligence and driving deal flow.
Annualised VC returns by
lead investor and series
The power is in the network
Portfolio
With a Limited Partner network comprised of specialist clinicans, senior MedTech industry executives and leaders of large investment funds, our collective knowledge base has allowed us to construct a portfolio of technologies with the potential to both dramatically improve patient outcomes and yield significant returns.
The more human way to deliver radiation therapy
MedTech Expertise. Commercial Experience. Global Perspective.
Our team has lived and breathed the medical technology commercialisation journey.
Our General Partners, Investment Committee and Advisory Board bring decades of experience across medical technology, healthcare, investment and commercialisation. This combination of capital, commercial expertise, healthcare knowledge and global networks gives our portfolio companies the support they need to navigate the complex journey from innovation to impact. Collectively, our team has:
01
Managed some of the world's largest global MedTech companies
02
Led some of Australia's largest hospitals
03
Founded venture funds investing in novel medical technologies
04
Built MedTech companies from the ground up
05
Taken companies through successful acquisition by multinational organisations
06
Built businesses that have gone on to list on the ASX
07
Advised MedTech company boards on capital raising and M&A
The Bioshore Team
There is no other venture fund in Australia with this breadth of experience and track record in driving successful clinical and commercial outcomes in medical technology
Jeff is an experienced medical technology professional with a demonstrated history of developing and commercialising products across a broad range of therapeutic and diagnostic fields. As an entrepreneurial professional with a Bachelor of Science majoring in Neuroscience from Macquarie University, Jeff has founded, invested in and successfully exited a number of medical technology businesses. Jeff currently acts as a corporate adviser to, and sits on the board of, a number of Australian and NZ MedTech companies
Jeff Reid
General Partner
.png)
A seasoned leader in the medical technology community, Andrew has served as Group President at Stryker, Chairman at Optimized Ortho, CEO at Global Orthopaedic Technology and most recently President - International at Enovis. Having worked as a senior executive in various MNCs through to early stage start ups, Andrew has developed a unique skillset spanning identification, commercialisation and acquisition of cutting edge medical technologies. He hold a BBus from Charles Sturt University and has completed the Advanced Management Program at Harvard Business School.
Andrew Fox-Smith
General Partner
David has over 25 years experience in venture capital, corporate finance, equity capital markets and M&A. He holds a Bachelor of Arts (Economic History, USYD), Bachelor of Laws (Hons) and is a Fellow of the Financial Services Institute of Australasia. David has held executive positions at Kleinwort Benson, Merrill Lynch & Co and GMCG. David was a co-founder of Ryder Capital and is managing general partner of the Ryder Innovation Fund, an early stage venture capital limited partnership. David has been a partner at Bioshore Ventures since March 2025. He currently serves on the board of Ryder Capital Ltd (ASX:RYD) and served on the board of Tetratherix Ltd (ASX:TTX) from March 2020 to December 2025.
David Bottomley
General Partner
As the current CEO of the North Shore Network and a former Director of the Australian Private Hospital Association, Rob brings a wealth of experience and commercial acumen in assessing the health economics of novel and emerging medical technologies.
Robert Cusack
Investment Committee
Jon is a highly experienced anaesthetist currently serving as the CoHead of Dept at Royal North Shore Hospital. In this role Jon works closely with a broad range of surgical specialties and as such provides invaluable clincal insight into medical technologies in due diligence.
Dr Jonothon Brock
Investment Committee
With a unique skill set and unmatched insights into the medical research and policy sectors, Anne has been at the forefront of MedTech in Australia for over 20 years via her role as the R&D Manager at The Children’s Hospital at Westmead for over 10 years and more recently taking responsibility for leading the development and implementation of major policies and government programs to enhance medical research capability in NSW. Anne currently serves at the Chief Commerical Officer at ANDHealth, Australia's only business accelerator dedicated to digital health commercialisation & investment readiness
Anne O'Neill
Advisory Board
A serial MedTech entrepreneur, Andy has developed over 18 patents for the treatment of complex spine pathologies and was a cofounder of the K2M Group (acquired by Stryker). Andy invests actively as a founder and managing partner of Neurospine Ventures, a US-based global medical technology investor group and has held numerous consulting, senior executive and board roles in companies spanning medical devices, novel diagnostics and biotechnologies
Andrew T Rock
Advisory Board
Spanning the worlds of cardiac, orthopaedic and biologic therapeutic innovations across both multinationals and startups, Will has launched, managed and scaled a range of cutting-edge medical technologies. With a degree in Medical Science from University of Technology Sydney, Will is currently the CEO of Tetratherix Ltd, an ASX listed, regenerative biologic therapy technology, developed at the University of Sydney
Will Knox
Advisory Board
Invest in the Future of Medical Technology
Partner With Bioshore Ventures
At Bioshore Ventures, we provide the support and resources medical technology innovators need to thrive and make a meaningful impact on the world.
We welcome conversations with founders, innovators and investors who share our commitment to advancing healthcare through medical technology.
Invest in the Future of Medical Technology
Partner With Bioshore Ventures
At Bioshore Ventures, we provide the support and resources medical technology innovators need to thrive and make a meaningful impact on the world.
We welcome conversations with founders, innovators and investors who share our commitment to advancing healthcare through medical technology.
This website is authorised by Bioshore Capital Pty Ltd (ACN 684 995 560) ("Bioshore Capital"), the investment manager of Bioshore Ventures Fund I, an Early Stage Venture Capital Limited Partnership (ESVCLP Fund). Bioshore Capital is a Corporate Authorised Representative (AR 001314515) of Polar 993 Advisory Pty Ltd (ACN 649 554 932) (AFSL 531197) ("Polar Advisory"). The ESVCLP Fund is registered as an early stage venture capital limited partnership and as a complying and fully registered early stage venture capital fund in accordance with the Venture Capital Act 2002 (Cth). Bioshore Capital's authority under its Corporate Authorised Representative Agreement with Polar Advisory is limited to general advice regarding the ESVCLP Fund and only to wholesale clients. Polar 993 Limited (ACN 642 129 226) (AFSL 525458) ("Polar 993") has entered into an Intermediary Authorisation Arrangement with Bioshore GP Pty Ltd, the general partner of the ESVCLP Fund ("General Partner"), for the making of offers for the issuing, variation or disposal of interests in the ESVCLP Fund. Any information contained on this website is of a general nature only and is not to be taken to contain any financial product advice or recommendation. Nothing in this website is intended as financial product advice and it does not take into account any person's investment objectives, financial circumstances or specific needs. This presentation is neither an offer to sell nor a solicitation of any offer to acquire interests or any other investment and should not be used as the basis for making an investment in the ESVCLP Fund. Bioshore Capital, Polar 993 and Polar Advisory and their directors, officers, employees, agents or associates do not guarantee repayment of capital, the performance of any fund or any service. Past performance is not a reliable indicator of future performance.
© 2026 by Bioshore Capital Pty Ltd